Article: RENAGEL SIGNIFICANTLY SLOWS PROGRESSION OF CARDIAC CALCIFICATION; NEW STUDY RESULTS ANNOUNCED.

PR Newswire, London, June 26. This press release is transmitted on behalf of Genzyme

Vienna, Austria -

Kidney dialysis patients experienced no significant progression of cardiac calcification when using Renagel(R) (sevelamer hydrochloride), a calcium-free, aluminium-free medication designed to control phosphorus in their bloodstream, according to study results released today. Conversely, patients using calcium-based phosphate binders continued to develop cardiac calcification, a form of cardiovascular disease in which calcium deposits form within the blood vessels around the heart.

The study, which was presented at the European Dialysis and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!